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Abstract

Purpose: Coronary artery bypass graft is the standard
treatment for unprotected left main disease; however, some
patients are poor surgical candidates due to comorbidities.
We assessed the safety and clinical outcome of elective,
unprotected left main coronary artery stenting in nonsurgical
patients.
Methods: Between October 2004 and June 2006,
50 consecutive patients underwent elective, unprotected
left main coronary artery stenting at our institution. Patients
were followed for a median of 16 and 96 months and clinical
outcomes monitored.
Results: Median logistic euroSCORE was 28.6 (interquartile
range: 14.6-43.4). Median baseline left ventricular ejection
fraction (LVEF) was 50%. Procedural success rate was
100%. The rates of cerebrovascular accident, myocardial
infarction, target vessel revascularization and cardiovascular
death were 2%, 4%, 4% and 2%, respectively, at 30 days,
2%, 6%, 6% and 2% at 16 months, and 2%, 6%, 12% and
4% at 96 months. Major adverse cardiac and cerebrovascular
event rate was 12% at 30 days, 16% at 16 months and 24% at
96 months. Median LVEF at 16 months was 55%,
significantly improved from baseline (P<0.001).
Conclusion: In nonsurgical patients with left main disease,
stenting of the unprotected left main coronary artery is
safe, with acceptable rates of major adverse cardiac and
cerebrovascular event up to 96 months poststenting.
(J Patient-Centered Res Rev. 2014;1:114-120.)
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Introduction

Coronary artery bypass graft (CABG) surgery is the standard
treatment for left main coronary artery (LMCA) stenosis,
based primarily on studies showing significant survival benefit
of CABG compared with medical therapy.1,2 According
to the 2005 American College of Cardiology/American
Heart Association/Society for Cardiac Angiography and
Interventions guidelines, percutaneous coronary intervention
(PCI) of unprotected LMCA is considered a class IIa
indication for patients ineligible for CABG and a class
III indication for patients eligible for CABG.3 In the 2009
updated guidelines, LMCA stenting was designated class IIb
in patients with anatomic conditions associated with a low
risk of PCI procedural complications and clinical conditions
that predict an increased risk of adverse surgical outcomes.4
Use of bare-metal stents for LMCA disease has been
associated with high 1- to 2-year mortality rates, averaging
17% (range: 3-31%), and repeat revascularization rates,
averaging 29% (range: 15-34%).5 The introduction of drugeluting stents (DES) has revolutionized PCI, improving
clinical outcomes over bare-metal stenting and reducing the
need for target lesion revascularization due to restenosis.
Results of studies on the use of DES in the treatment of
unprotected LMCA stenosis are encouraging.6-9
We evaluated safety and clinical outcome of elective
unprotected LMCA stenting in patients deemed to be
nonsurgical candidates at our institution.

Methods

Population
We retrospectively identified all consecutive adult patients
who underwent elective, unprotected LMCA stenting at our
institution between October 2004 and June 2006. We excluded
patients who underwent emergent LMCA stenting or protected
LMCA stenting. The study was fully supported by the hospital
administration and approved by the institutional review board.
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Procedures
Indications for LMCA stenting included unstable angina,
non-ST-segment elevation myocardial infarction (NSTEMI),
or evidence of myocardial ischemia on stress testing.
Patients were risk-stratified for CABG according to the
European System for Cardiac Operative Risk Evaluation
(euroSCORE). Both standard and logistic euroSCORES were
calculated for each patient, since the standard euroSCORE
may underestimate the risk in very high-risk patients.
All procedures were performed according to concurrent
guidelines. Choice of stent (drug-eluting or bare-metal),
stenting technique, debulking before stenting, intravascular
ultrasound guidance, prophylactic intraaortic balloon pump
use, and anticoagulation/antiplatelet regimen (bivalirudin,
glycoprotein IIb/IIIa inhibitors, and/or heparin/enoxaparin)
was at the discretion of the treating interventional
cardiologist. Appropriate informed consent for the procedure
was obtained from all patients.
Unless otherwise contraindicated, all patients received
clopidogrel (75 or 300 mg loading dose) and aspirin
(325 mg) prior to intervention. After the procedure and in the
absence of contraindications, patients were prescribed aspirin
(325 mg daily initially, followed by 81 to 325 mg for life) and
clopidogrel bisulphate (75 mg daily for at least 12 months and
continued long term if well tolerated and no contraindication).
All patients were monitored for at least 24 hours in the
coronary intensive care unit. All patients received follow-up,
with the first visit within 4-6 weeks of procedure.
Indications for repeat angiography were acute coronary
syndrome, stable angina with evidence of ischemia on
stress testing, or routine follow-up angiogram. Repeat
revascularization was done when needed.
Definitions
Procedural success rate was defined as residual stenosis of less
than 20% and establishment of Thrombolysis in Myocardial
Infarction (TIMI)-3 flow without major periprocedural
adverse event (death, myocardial infarction, emergency
revascularization). NSTEMI was defined as elevation
of cardiac markers (troponin-I and creatine kinase-MB)
above the upper limits of normal, per our laboratory standard,
without ST-segment elevation on electrocardiogram.
ST-segment elevation myocardial infarction (STEMI)
was defined as at least 1 mm of ST-segment elevation
in at least two contiguous leads and reciprocal
changes with or without elevated cardiac markers.
Unstable angina was defined as new-onset angina, rest
angina, angina of increasing frequency or intensity, or angina
Original Research

lasting longer than 20 minutes. Major adverse cardiac and
cerebrovascular event (MACCE) was defined as cardiac death,
myocardial infarction, target vessel revascularization (TVR)
and cerebrovascular accident. TVR was defined as repeat
revascularization (PCI or CABG) caused by LMCA stenosis.
Endpoints
The primary endpoint was MACCE at 30 days, at 16 months
and at 96 months. Secondary endpoints were improvement
in left ventricular ejection fraction (LVEF) and rate of major
periprocedural complications.
Statistical Analysis
Continuous variables were presented as medians with
interquartile ranges (IQR). Categorical variables were
presented as counts and percentages. Baseline and follow-up
LVEF were compared using Wilcoxon signed-rank test.
Association between certain variables and MACCE incidence
was evaluated using chi-square or Fisher’s exact tests. A
two-tailed value of P<0.05 was considered statistically
significant. All statistical analysis was performed using SAS
Version 9.2 (SAS Institute Inc., Cary, NC).

Results

Baseline Patient Characteristics
Between October 2004 and June 2006, 50 consecutive
patients underwent elective, unprotected LMCA stenting
at our institution. Baseline characteristics are presented in
Table 1. Median age was 74.3 years. There were more males
(60%) than females. All patients were at high surgical risk
with median logistic and standard euroSCORES of 28.6 and
12, respectively. There was a prevalence of history of coronary
artery disease with prior myocardial infarction in 60%, CABG
in 44% and PCI in 40% of patients. The most prevalent risk
factor for coronary artery disease was hypertension (84%),
followed by dyslipidemia (76%), peripheral artery disease
(52%), smoking (46%), diabetes mellitus (44%) and renal
failure (40%). Median LVEF was 50%, with most values
falling between 35% and 55%. Prior congestive heart failure
was present in 40% of patients. All patients received dual
antiplatelet therapy. A high percentage of patients received
statins (90%), beta blockers (84%) and angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers (70%).
Lesion and Procedural Data
Lesion and procedural characteristics are presented in Table 2.
Median LMCA stenosis was 80%. The majority of lesions were
de novo lesions (96%). About two-thirds of the LMCA lesions
were at the distal bifurcation (68%), consistent with reported
data in the literature. The ostial and proximal LMCA was
involved in 24% of patients, while the mid-LMCA was involved
www.aurora.org/jpcrr
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Table 1. Baseline patient characteristics

Table 2. Lesion and procedural characteristics

Characteristic
Demographics
Median age, years (IQR)
Female
Median logistic euroSCORE (IQR)
Median standard euroSCORE (IQR)

n=50 (100%)
74.3 (64.5-81.7)
20 (40%)
28.6 (14.6-43.4)
12 (9-14)

Medical history
Median left ventricular ejection fraction (IQR)
Cardiogenic shock
Prior myocardial infarction
Prior percutaneous coronary intervention
Coronary artery bypass graft
Valve replacement
Atrial fibrillation
Congestive heart failure
Implantable cardioverter-defibrillator
Permanent pacemaker
Renal failure
Dyslipidemia
Diabetes mellitus
Cigarette smoker
Chronic lung disease
Peripheral artery disease
Cerebrovascular accident
Hypertension
Medications
Aspirin
Clopidogrel
Beta blocker
Calcium channel blocker
ACEI/ARB
Nitrates
Statin drugs

50% (35-55)
2 (4%)
30 (60%)
20 (40%)
22 (44%)
1 (2%)
9 (18%)
21 (42%)
2 (4%)
5 (10%)
20 (40%)
38 (76%)
22 (44%)
23 (46%)
16 (32%)
26 (52%)
8 (16%)
42 (84%)
50 (100%)
50 (100%)
42 (84%)
10 (20%)
35 (70%)
30 (60%)
45 (90%)

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; IQR, interquartile range.

in 8%. More patients received bivalirudin (54%) alone than
a combination of heparin and IIb/IIIa inhibitors (46%).
A total of 67 stents were deployed, predominantly DES (94%).
Two stents were deployed in the LMCA in 66% of patients,
whereas a single stent was deployed in 17%. Kissing technique
was used in 24% and crush technique in 10%. Debulking prior
to stent deployment was used in 6% of patients. Prophylactic
intraaortic balloon pump was used in 6%. Postintervention
TIMI-3 flow and residual stenosis less than 20% were achieved
in all patients. Procedural success rate was 100% (Table 3).
Primary Endpoint
Clinical outcomes recorded at two median follow-up periods
(16 and 96 months) are presented in Table 4. At 30 days,
incidence of myocardial infarction, cerebrovascular accident,
TVR and cardiac death was 4%, 2%, 4% and 2%, respectively.
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Characteristic
Severity of stenosis
LMCA stenosis (IQR)
RCA stenosis (IQR)
LAD stenosis (IQR)
CIRC stenosis (IQR)

n=50 (100%)
80 (70-85)
80 (40-100)
80 (65-95)
80 (60-90)

Prior LMCA stent
De novo
In-stent

48 (96%)
2 (4%)

Stent type
Drug-eluting
Bare-metal

63 (94%)
4 (6%)

Lesion location
Ostial/proximal
Mid-segment
Distal

12 (24%)
4 (8%)
34 (68%)

Number of stents within LMCA
One
Two

33 (66%)
17 (34%)

Number of vessels stented
One
Two
Three
Four

5 (10%)
25 (50%)
19 (38%)
1 (2%)

Stenting technique
Kissing
Crush
Single
Rotational atherectomy
IABP use

12 (24%)
5 (10%)
33 (66%)
3 (6%)
3 (6%)

Medications
Heparin
Glycoprotein IIb/IIIa inhibitors
Angiomax

23 (46%)
23 (46%)
27 (54%)

CIRC, circumflex artery; IABP, intra-aortic balloon pump; IQR, interquartile
range; LAD, left anterior descending artery; LMCA, left main coronary artery;
RCA, right coronary artery.

Of the two patients who had myocardial infarction, one
had STEMI and was treated with CABG and the other had
NSTEMI and was treated with repeat PCI. At 16 months,
incidence of myocardial infarction, cerebrovascular accident,
TVR and cardiac death was 6%, 2%, 6% and 2%, respectively.
Beyond 30 days and up to 16 months, there was one NSTEMI
and one repeat PCI. At 96 months, incidence of myocardial
infarction, cerebrovascular accident, TVR and cardiac death
was 6%, 2%, 12% and 4%, respectively. MACCE rate was
12% at 30 days, 16% at 16 months and 24% at 96 months.
Secondary Endpoints
Periprocedural complications are presented in Table 3.
Evaluation for major complications included: emergent CABG,
Original Research

Table 3. Procedural outcomes
Variable
Procedural success
Residual stenosis
0%
Less than 20%
More than 20%
Post-PCI TIMI-3 flow
Procedural success
Periprocedural complications
Postprocedure cardiogenic shock
Vascular perforation
LMCA dissection
Abrupt closure
Tamponade
Aortic dissection
Emergent CABG
Death
Other complication

n=50 (100%)

46 (92%)
4 (8%)
0
50 (100%)
50 (100%)
0
0
0
0
0
0
0
0
0

CABG, coronary artery bypass graft; LMCA, left main coronary artery;
PCI, percutaneous coronary intervention; TIMI, Thrombolysis in
Myocardial Infarction.

LMCA dissection, abrupt vessel closure, vascular perforation,
cardiac tamponade, procedure-related cardiogenic shock and
procedure-related death. There were no major periprocedural
complications. Median baseline LVEF was 50% (IQR:
35-55%). Median follow-up LVEF was 55% (IQR: 45-60%).
Two-tailed Wilcoxon signed-rank test showed significant
overall improvement (+5%) in LVEF (P<0.001) (Table 4).
Predictors for MACCE
Certain clinical variables, including age, gender, history of
myocardial infarction, PCI, diabetes mellitus, renal failure
and baseline LVEF, were tested for possible association with
MACCE at 16 months (Table 5). No association, except baseline
renal failure (P=0.047), was documented. Lesion location, stent
type, stenting technique, number of stents, and number of vessels
stented also were tested for their possible association with
MACCE at 16 months. No significant associations were found.

Discussion

Use of PCI for LMCA stenosis has been an area of great
debate, and CABG remains the standard of care. Initial
attempts at percutaneous transluminal coronary angioplasty
in LMCA were discouraging.10,11 Our study shows
unprotected LMCA stenting is feasible and safe in high-risk
patients. Our procedure success rate was 100%, and there
were no major procedure-related complications.
This single-center study is a reflection of “real-world”
outcomes. All patients were at very high surgical risk, with
Original Research

Table 4. Clinical outcomes at short-, intermediate- and long-term
follow-up
Variable

n=50 (100%)

Short-term (30-day) outcome
Myocardial infarction
STEMI
NSTEMI
Cerebrovascular accident
Target vessel revascularization
CABG
PCI
Cardiovascular death
MACCE*

2 (4%)
1 (2%)
1 (2%)
1 (2%)
2 (4%)
1 (2%)
1 (2%)
1 (2%)
6 (12%)

Intermediate-term (16-month) outcome
Myocardial infarction
STEMI
NSTEMI
Cerebrovascular accident
Target vessel revascularization
CABG
PCI
Cardiovascular death
All PCI
MACCE*
Mean follow-up LVEF (IQR)
Mean improvement of LVEF (IQR)
Improved LVEF
Same LVEF
Worsened LVEF
Long-term (96-month) outcome
Myocardial infarction
STEMI
NSTEMI
Cerebrovascular accident
Target vessel revascularization
CABG
PCI
Cardiovascular death
All PCI
MACCE*

3 (6%)
1 (2%)
2 (4%)
1 (2%)
3 (6%)
1 (2%)
2 (4%)
1 (2%)
8 (16%)
8 (16%)
55% (45-60)
5% (0-10)†
31 (62%)
13 (25%)
6 (12%)
3 (6%)
1 (2%)
2 (4%)
1 (2%)
6 (12%)
2 (4%)
4 (8%)
2 (4%)
20 (40%)
12 (24%)

*MACCE includes cerebrovascular accident, myocardial infarction, target
vessel revascularization and death from cardiovascular disease.
†LVEF was significantly improved compared with baseline LVEF
(P<0.001, two-tailed Wilcoxon signed-rank test).
CABG, coronary artery bypass graft; IQR, interquartile range; LVEF,
left ventricular ejection fraction; MACCE, major adverse cardiac and
cerebrovascular event; PCI, percutaneous coronary intervention; STEMI,
ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction.

median estimated perioperative mortality of 28.6% (IQR:
14.4-43.4%). These patients were appropriately declined
by surgeons and treated with LMCA stenting in accordance
with concurrent guidelines. Although all patients were
high risk, and 68% of them had lesions located in the
distal bifurcation segment (the most problematic lesion
www.aurora.org/jpcrr
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Table 5. Predictors of MACCE incidence at 16-month follow-up
Overall
n=50

No MACCE
n=42

MACCE
n=8

P-value*

74.3 (64.5-81.7)
20 (40%)
30 (60%)
20 (40%)
22 (44%)
20 (40%)
22 (44%)
50% (35-55)

74.9 (65.8-81.8)
16 (38.1%)
24 (57.1%)
17 (40.5%)
17 (40.5%)
14 (33.3%)
19 (45.2%)
50% (35-55)

71.7 (60.4-76.7)
4 (50.0%)
6 (75.0%)
3 (37.5%)
5 (62.5%)
6 (75.0%)
3 (37.5%)
53% (24-58)

0.478
0.697
0.345
1.000
0.277
0.047
1.000
0.748

Prior LMCA stent
De novo
In-stent

48 (96%)
2 (4%)

40 (95.2%)
2 (4.8%)

8 (100%)
0 (0%)

1.000

Stent type
Drug-eluting
Bare-metal

46 (92%)
4 (8%)

38 (90.5%)
4 (9.5%)

8 (100%)
0 (0%)

0.842
1.000

Lesion locations
Ostial
Proximal
Mid
Distal

11 (22%)
1 (2%)
4 (8%)
34 (68%)

9 (21.4%)
1 (2.4%)
3 (7.1%)
29 (69.1%)

2 (25.0%)
0 (0%)
1 (12.5%)
5 (62.5%)

1.000
1.000
0.514
0.699

No. of stents within LMCA
One
Two

33 (66%)
17 (34%)

27 (64.3%)
15 (35.7%)

6 (75.0%)
2 (25.0%)

0.699

No. of vessels stented
One
Two
Three
Four

5 (10%)
25 (50%)
19 (38%)
1 (2%)

4 (9.5%)
22 (52.4%)
15 (35.7%)
1 (2.4%)

1 (12.5%)
3 (37.5%)
4 (50%)
0 (0%)

1.000
0.702
0.459
1.000

Stent technique
Kissing
Crush
Single

12 (24%)
6 (12%)
32 (64%)

10 (23.8%)
6 (14.3%)
26 (61.9%)

2 (25.0%)
0 (0%)
6 (75%)

1.000
0.572
0.760

Characteristic
Demographics
Median age, years (IQR)
Female
Myocardial infarction
PCI
Diabetes mellitus
Renal failure
CABG
Median LVEF (IQR)

*P-values were calculated by chi-squared tests or Fisher’s exact tests (two-tailed).
CABG, coronary artery bypass graft; IQR, interquartile range; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; MACCE, major
adverse cardiac and cerebrovascular event; PCI, percutaneous coronary intervention.

presentation), MACCE rates at 30 days (12%), 16 months
(16%) and 96 months (24%) were within an acceptable
range. Cardiovascular mortality (2% at 30 days, 2% at
16 months, 4% at 96 months) and TVR (4% at 30 days, 6%
at 16 months, 12% at 96 months) were similar or lower than
the rates reported in the studies later discussed. It must be
noted that the majority of patients received DES.
A review of eight studies on LMCA stenting using bare-metal
stents reported increased 1- to 2-year mortality (17%) and
repeat revascularization rates (29%).4 The Unprotected Left
Main Trunk Intervention Multicenter Assessment (ULTIMA)
registry demonstrated a high 1-year cardiac mortality rate of
20.2% in high-risk patients and patients with low LVEF.12 In
our study, 4 patients were stented with bare-metal stents; none
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experienced MACCE complications. The availability of larger
diameters in the newer DES may resolve the issue of having
to choose bare-metal stents over DES due to vessel size.
The advent of DES renewed the hope for a percutaneous
alternative to surgery in the treatment of LMCA disease.
Erglis et al. reported better major adverse cardiac event
(MACE)-free survival rates with paclitaxel-eluting stents
compared to bare-metal stents (87% vs. 70%).13 Similarly,
Park et al. reported better 1-year freedom from death,
myocardial infarction and TVR with sirolimus-eluting stents
compared to bare-metal stents (98.0% vs. 81.4%).8 More
recently, Kubo and colleagues demonstrated the incidence
of target lesion revascularization at 7 years was significantly
lower in DES compared to bare-metal stents (26.4% vs.
Original Research

40.5%, P=0.009), although incidence rates at 1-4 years and
beyond 4 years were similar. In addition, the incidence of
cardiac death or nonfatal myocardial infarction was similar
between the two groups.14 The Drug-Eluting Stent for Left
Main (DELFT) Registry followed patients with emergent
and elective unprotected LMCA stenting with DES for up
to 3 years. Incidence of cardiac death at 30 days, 1 year and
3 years was 3.3%, 6.7% and 9.2%, respectively. Incidence
of TVR was 0.8%, 10% and 14.2%, respectively. MACE
rate was 11.4%, 24.3% and 32.1%. MACE was significantly
higher with emergent PCI at 30 days and 1 year, while cardiac
death was significantly higher with emergent PCI at 3 years.15
These studies demonstrate favorable short- and long-term
outcomes with elective unprotected LMCA stenting.
There is a paucity of large randomized trials directly
comparing DES and CABG for unprotected LMCA. This
might be, in part, due to CABG being considered the standard
of care treatment for significant LMCA stenosis and the
feared consequences of stent thrombosis in LMCA. Early
reports documented mortality rates of 1.7-7.0% following
CABG for LMCA stenosis, and 1-year mortality rates of
6-14% are reported in more contemporary retrospective
studies.16-18 The Revascularization for Unprotected Left Main
Coronary Artery Stenosis: Comparison of Percutaneous
Coronary Angioplasty Versus Surgical Revascularization
(MAINCOMPARE) registry compared unprotected LMCA
stenting (71% DES) with CABG in 2,240 nonrandomized
patients. This study showed a significantly lower rate of
freedom from repeat revascularization with DES at 3 years
than with CABG (90.7% vs. 98.4%, P=0.001). Threeyear all-cause mortality was not different (6.1% in PCI
group, 8.3% in CABG group). There were no significant
differences in rate of death or the composite endpoint of
death, Q-wave myocardial infarction, or stroke between
patients receiving stents and those undergoing CABG.19,20
In our study, rate of cardiac death was 2% at 30 days, 2% at
16 months and 4% at 96 months, lower or similar to CABG
rates. The Study of Unprotected Left Main Stenting Versus
Bypass Surgery (LE MANS) was a small randomized trial
that compared unprotected LMCA stenting with CABG
in relatively low-risk patients with normal LVEF. Thirtyday MACCE was lower with PCI. One-year MACCE-free
survival was similar in the two groups. A trend towards
improved survival was seen with PCI. LVEF improved
in the PCI group.21 In the randomized Synergy Between
Percutaneous Coronary Intervention With TAXUS and
Cardiac Surgery (SYNTAX) trial that compared CABG
with PCI for left main/multivessel disease, there were
705 patients with LMCA disease (CABG: 348 patients,
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PCI: 357 patients). For this group of patients, the overall
safety endpoint of death, myocardial infarction and
cerebrovascular accident was similar (P=0.29) for CABG
(9.1%) and PCI (7.0%). Overall MACCE also was similar
(CABG: 13.6%, PCI: 15.8%, P=0.44). PCI was associated
with better MACCE rates compared with CABG in the
subset of patients with isolated LMCA disease (7.1% vs.
8.5%) or LMCA with 1-vessel coronary artery disease
(7.5% vs. 13.2%).22 Park et al. followed 350 patients with
unprotected LMCA disease who underwent PCI (with
bare-metal stents) or CABG over a 10-year period and 395
patients with unprotected LMCA disease who underwent
PCI with DES or CABG over a 5-year period.23 In the
10-year follow-up cohort of bare-metal stents and concurrent
CABG, the adjusted risks of death (hazard ratio [HR]: 0.81;
95% confidence interval [CI]: 0.44-1.50; P=0.50) and the
composite of death, Q-wave myocardial infarction, or stroke
(HR: 0.92; 95% CI: 0.55-1.53; P=0.74) were similar between
the two groups. The rate of TVR was significantly higher in
the group that received bare-metal stents (HR: 10.34; 95%
CI: 4.61-23.18; P<0.001).23 In the 5-year follow-up cohort
of DES and concurrent CABG, there was no significant
difference in the adjusted risk of death (HR: 0.83; 95%
CI: 0.34-2.07; P=0.70) or the risk of the composite
outcome (HR: 0.91; 95% CI: 0.45-1.83; P=0.79). The rates
of TVR also were higher in the DES group than the CABG
group (HR: 6.22; 95% CI: 2.26-17.14; P<0.001).23 These
results are encouraging for use of DES in the treatment of
unprotected LMCA. The MACCE and cardiac mortality
rates reported in our study are consistent with these results.
Our study showed significant improvement in LVEF postPCI. Significant improvement in LVEF post-PCI compared
with CABG was reported in the LE MANS study. This
differential improvement in LVEF was explained, in part,
by restoration of physiologic anterograde flow in the LMCA
and major vessels, lack of perioperative reperfusion injury
and low incidence of myocardial infarction.21
Some authors reported predictors for adverse events
following unprotected LMCA stenting. These included age,
high euroSCORE, reduced LVEF, insulin-dependent diabetes
mellitus and multiple stenting.15,24 In our study, no association
was found between MACCE and age, gender, history
of myocardial infarction, PCI, diabetes, baseline LVEF or
euroSCORE. However, there was an association between
baseline renal failure and MACCE (P=0.047). Lesion location,
stent type, stenting technique, number of stents and number
of vessels stented did not predict MACCE. Ability to see
differences may have been hindered by the low MACCE rate.

www.aurora.org/jpcrr
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Study Limitations
There are some limitations to this study. The study population
size is small; use of unprotected LMCA stenting is limited
by current guidelines to patients ineligible for surgery. No
direct comparison with CABG was done. Intravascular
ultrasound and routine angiographic follow-up was not done
in all patients. Given the high surgical risk in our patients,
the results of this study may not be extrapolated to patients
at lower surgical risk.

Conclusion

In nonsurgical patients with left main disease, stenting of
unprotected left main coronary artery is safe, with acceptable
rates of MACCE seen up to 96 months poststenting.
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